HDAC6 and cancer: However, selective HDAC6 inhibitors alone were reported to be inadequate as anti-cancer compounds, and it was suggested that an anti-metastatic drug should be a non-selective HDACi or a selective HDAC6i in combination with other chemotherapeutics [25].